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weeks before the transplant and then at days 0, 30,100 and
180. Other data includes GFRwhich is calculated by using the
Cockcroft Gault formula at the same intervals, sub-type of
MM and Durie-Salmon stage at diagnosis, disease response
to therapy, BMI at baseline; and other comorbidities such as
diabetes, hyperlipedemia and coronary artery disease.
Statistical analyses were performed using the statistical
package of SPSS version 18. All P-values were 2-sided.
Results: In this study 184 patients were included. The sample
demographics at baseline arepresented inTable 1. Association
between BP stages and disease status before ASCT and at day
0was statistically signiﬁcant (p¼.025 , X2¼14.408); therewas
no statistically signiﬁcant association between stages of HTN
at 0 , 30,100 and180daysafter theASCT in regards to age , race
or gender. Mean Systolic and diastolic BP-value showed no
statistically signiﬁcant difference at the same intervals
respectively. In addition, there was no correlation between
stages of HTN, and stages or type ofMM. The only statistically
signiﬁcant association between chronic kidney disease (CKD)
stages and BP stages was at day 0 (day ASCT infused) (P¼.032,
X2 ¼26.670. The association between CKD stages and diseaseTable 1
Demographic characteristics of the simple
Patient Characteristics Number (%)
Gender
Male 100 (54%)
Median age years (range) 59 (33-73)
Race
White 138 (75%)
African-American 41 (22%)
Other 5 (3%)
Marital status
Never married 18 (10%)
Now married 127 (69%)
Separated 13 (7%)
Widowed 6 (3%)
Divorced 20 (11%)
Health insurance
Medicare 180 (98%)
Other 4 (2%)
BMI
Normal 42 (23%)
Overweight 64 (35%)
Obese 42 (23%)
Severely obese 36 (19%)
BP stage
Normal 32 (17%)
Prehypertension 78 (43%)
Stage 1 HTN 64 (35%)
Stage 2 HTN 19 (5%)
CKD stage
1 60 (33%)
2 82 (45%)
3A 24 (13%)
3B 10 (5%)
4 5 (3%)
5 3 (1%)
Myebma stage
IA 17 (19%)
IIA 25 (14%)
IIIA 130 (71%)
IIIB 12 (6%)
Disease status
VGPR 65 (35%)
PR 57 (31%)
CR 26 (14%)
SD 18 (10%)
PD 16 (9%)
SCR 2 (1%)
Melphalan dose
200 mg 140 (76%)
140 mg 44 (24%)status at 100 days aftermelphalanwas statistically signiﬁcant
(P¼.043, X2¼25.568). The associations betweenBP stages and
BMI stages were borderline or statistically signiﬁcant at 30
days (P¼.054 and X2¼16.665), 100 days (P¼.026 and
X2¼18.947) and 180 days(P¼.001, X2¼27.120).
Conclusion: There was no direct effect of ASCT on blood
pressure improvement. Other factors such as BMI and
disease status at baseline appear to play more roles on Bp
control. Majority of our patient were transplanted at early
stages of (CKD) which can explain the result. We suggest
a prospective study that evaluates the impact of ASCT in MM
patients with high BP.
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No standard method for HSC mobilization prior to autolo-
gous stem cell transplant (ASCT) exists. We performed
a retrospective analysis on consecutive adult patients (pts)
undergoing mobilization for ASCT between 1/2009 and 1/
2012 to compare efﬁcacy of mobilization method and trans-
plant outcome.Method ofmobilizationwas per the discretion
of the attending physician. Chemotherapy andG-CSF (Chemo/
G)were used if therapyor cytoreductionwas necessary for the
underlying malignancy. Per institutional guideline cytokine
onlymobilizationusedG-CSF (G)10ug/kgdailywithapheresis
startingonday5andplerixafor (G/P)0.24mg/kgwasaddedon
day 4 if the peripheral bloodCD34+ cells/ulwas< 15. A total of
343 pts underwent 362 attempts at collection, 192 with G/P,
135 with G alone, and 35 after chemo/G. The median days of
apheresis for all three groups was 2 (range 1-4) and the
number of cumulative CD 34 cells collected after mobilization
was5.7(0-19), 6.8 (1.9-20.9), and6.3(0-19)million/kg in theG/
P, G, and chemo/G groups, respectively (p¼NS). Failure to
mobilize CD34 cells was deﬁned as never reaching 10 or
greater peripheral blood CD34+ cells/ul or collecting less than
2millionCD34+ cells/kg. Per institutional guideline 192 of 327
collections (59%) starting with G-CSF alone required the
addition of plerixafor. Nine of 192 collections (4.6%) in the G/P
group failed tomobilize and 2were rescuedwith a secondG/P
mobilization. Twelve of 35 collections (34%) in the chemo/G
group failed to mobilize and 8 were subsequently mobilized
adequately with G/P. Overall, 11/343 (3.2%) pts failed to
mobilize adequate CD34+cells. Engraftment and day 100
transplant outcomes were not different between the groups.
In conclusion, themethodofmobilizingHSC for ASCTdoes not
seem to affect clinical outcome, pts that fail mobilization after
chemo/G for treatment of active disease or cytoreduction can
be remobilizedwithG/P, andour current institutionalprotocol
to beginmobilizationwithG alone and add plerixafor on day 4
as described above allows a high rate of mobilization success.
Further prospective studies are needed to assess pharmacoe-
conomic and quality of life issues related to HSC mobilization.
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Treatment of AL amyloidosis (AL) with high dose
melphalan and autologous stem cell transplant (HDM/SCT)
results in a high rate of durable complete hematologic
responses (CHR) associated with systemic clinical responses
and improvement in survival. However, patients with cardiac
involvement are at increased risk of treatment-related
mortality (TRM).
HDM/SCT was performed for thirty patients between
2000 and 2011. Risk stratiﬁcation based on organ dysfunc-
tionwas performed. Analyses of pre and post SCT treatments,
TRM in patients with and without cardiac involvement,
hematologic (HR) and organ responses, progression free
(PFS) and overall survival (OS) was performed.
The median age was 60 years (range, 41-72) and there
were 20 males (67%). Twenty (67%) had multi-organ
involvement, 7 (24%) had single organ involvement, 18 (60%)
had renal involvement and 12 (40%) had cardiac involvement.
Peripheral blood stem cells were mobilized with G-CSF
alone for 3e4 days. HDM was administered over two days
and adjusted depending on age, severity of cardiac disease
and performance status. Twenty (67%) patients received 200
mg/m2, 9 (30%) received 140 mg/m2 and 1 received 100mg/
m2 HDM.
TRM, deﬁned as deaths within 100 days of SCT, occurred
in 3 patients (10%), 2 had cardiac disease and 1 did not. No
deaths occurred during stem cell mobilization. Of the 12
patients with cardiac involvement, 2 died within 100 days
(from CHF and sepsis with NYHA III and I prior to SCT). Of the
18 patients without cardiac involvement, 1 patient died of
exsanguination from AL-involved splenic rupture (Fisher's
exact test, P ¼ .54). Of the 12 patients with cardiac involve-
ment, 8 had a septal wall thickness >1.1cm and 6 were >
1.3cm. Of the 9 patients that had BNP measurements, all
were >100 pg/mL and 4 were >500 pg/mL.
Fourteen patients (47%) patients achieved CHR and 7
(23%) achieved at least a partial hematologic response at 1
year following HDM/SCT. Organ speciﬁc responses at 1 year
were conﬁrmed in 8 subjects. Fifteen patients received
chemotherapy prior to HDM/SCT leading to a deeper HR
prior to transplant in 7 patients. Two patients received a 2nd
autologous transplant, 4 and 7 years after the ﬁrst and
remain alive and in remission.Figure 1.HDM/SCT for patients with AL amyloidosis with and without
cardiac involvement is feasibleand is associatedwithexcellent
2 and 5 -year PFS and OS rates (Figure 1). Due to the inherent
ﬂaws in using traditional biomarkers and cardiac MRI for
staging cardiac disease in the setting of renal dysfunction,
improved strategies are needed. We are currently assessing
theutilityof speckle trackingderivedmyocardial strain indices
as a means for early diagnosis of cardiac involvement and
response to therapy- an area in which standard echocardio-
graphic measurements have been disappointing. Informative
data have been identiﬁed in the serial strain analyses on 5
patients who are currently undergoing therapy for AL.151
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Background: Nodular lymphocyte predominant Hodgkin
Lymphoma (NLPHL) is a more indolent form of Hodgkin
Lymphoma that is usually associated with favorable
outcomes. There are few reports of refractory disease
requiring high dose chemotherapy and autologous stem cell
transplantation (ASCT). Long-term follow up and outcomes
of refractory NLPHL requiring ASCT are lacking in the litera-
ture. The aim of this study was to describe clinical charac-
teristics of relapsed refractory NLPHL and outcomes
following ASCT in a cohort of patients followed at a single
institution.
Methods: The actively maintained Mayo Clinic Lymphoma
Database includes all consenting consecutive patients with
lymphoma seen at Mayo Clinic Rochester. This was used to
retrospectively identify patients with NLPHL. The study was
approved by the Institutional Review Board. Pathology was
conﬁrmed by a hematopathologist. The clinical characteris-
tics, therapy and outcomes of patients with NLPHL were
analyzed.
Results: Between 1970 and 2010, 222 consecutive adult
patients with NLPHL were identiﬁed. The median follow-up
for the entire cohort was 20 years. Forty-six (20.7%) relapsed
during the course of the disease and 17 (7.6%) developed
a transformation to diffuse large B cell lymphoma. Of the 46
patients, 8 (17.4%) had local relapses and were treated with
radiation therapy while 38 (82.6%) were treated with
chemotherapy (19 of these 38 patients had no prior exposure
to chemotherapy). Nine patients (4% of the entire cohort,
19.6% of relapsed patients) had ASCT. BEAM (BCNU, etopo-
side, cytarabine and melphalan) conditioning chemotherapy
was used in 6 (66.7%) patients. The median age of this group
was 29 years (21-52) and the median number of prior regi-
mens was two. All nine patients had prior exposure to ABVD
(Adriamycin, bleomycin, vinblastine, dacarbazine) and
salvage platinum based therapy was used in three patients
(33.3%). The median time from diagnosis to ASCT was 73
months (10-348). Two patients relapsed after ASCT (time to
relapse was 4 and 22 months). Seven patients (77.8%)
remained disease free after a median follow up of 70 months
(32-119). The median overall survival in this group
